报价延迟最少15分钟:2026/03/12 01:16 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.69 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.55/--
|
|
企业价值
619.60M
|
| 资产负债 |
|
每股账面净值
-0.00
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.91M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THVis a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States. |
